Sensorineural hearing impairment resulted from radiochemotherapy in patients with nasopharyngeal carcinom
10.3760/cma.j.issn.1004-4221.2009.02.093
- VernacularTitle:放化疗和单纯放疗鼻咽癌所致感音神经性听力损失分析
- Author:
Yumei WEI
;
Baosheng LI
;
Anting XU
;
Limin ZHAI
;
Haiqun LIN
- Publication Type:Journal Article
- Keywords:
Nasopharyngeal neoplasms/radiotherapy,Intensity modulated;
Nasopharyngeal neo-plasms/radioehemotherapy;
Hearing impaired,sensorineural
- From:
Chinese Journal of Radiation Oncology
2009;18(2):93-95
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the severity of sensorineural hearing impairment resulted from radiotherapy (RT) and radiochemotberapy (CRT) in patients with nasopharyngeal carcinoma (NPC). Methods Between March 2002 and May 2007, 100 initially diagnosed NPC patients in Shandong Tumor Hospital and Qi Lu Hospital were randomized to RT group and CRT group. All patients underwent intensity modulated radiation therapy. In CRT group, concurrent and adjuvant CDDP were administered (CDDP 25 mg/m2/d for 3 days to 4 cycles). Pure tone auditory threshold examination was performed 1 week ,6 months, 1 year and 2 years after the completion of radiotherapy. Statistical analyses were performed using Mann-Whit-ney U test,chi-square test and Fisber's exact probability test. Results The high-frequency threshold was significantly increased in CRT group comparing with RT group at 1- and 2-year after the treatment. In RT group, the hearing threshold was impaired immediately after the treatment, partially recovered within the first year but impaired again after 2 years. In CRT group, hearing threshold was impaired at the same time and kept getting worse until 1 year after radiotherapy, which could not be recovered. Conclusions Patients with NPC treated with radiotherapy and concurrent/adjuvant chemotherapy have more severe sensorineural hearing impairment comparing with those with radiotherapy alone, especially to the high frequency sound in the speech range. Inner ear tissue tolerance should be redefined for patients receiving radiochemotherapy.
